Abiopharma

China Medical System Holdings Limited (the “Company”, and together with its subsidiaries, the “Group”) is a platform company linking pharmaceutical innovation and commercialisation with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
The Group focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. The Group deeply engages in several specialty therapeutic fields, and has developed proven commercialisation capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. The Group continues to drive the in-depth development of its advantageous specialty areas to strengthen the competitiveness of its cardio-cerebrovascular, gastroenterology, and ophthalmology businesses.
The Group actively advances its “Glocalization” strategy, with Singapore as its regional headquarters for its Southeast Asia and Middle East business.

Additional info from SGX:

China Medical System Holdings Limited (the “Company”, and together with its subsidiaries, the “Group”) is a platform company linking pharmaceutical innovation and commercialisation with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
The Group focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. The Group deeply engages in several specialty therapeutic fields, and has developed proven commercialisation capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. The Group continues to drive the in-depth development of its advantageous specialty areas to strengthen the competitiveness of its cardio-cerebrovascular, gastroenterology, and ophthalmology businesses.
The Group actively advances its “Glocalization” strategy, with Singapore as its regional headquarters for its Southeast Asia and Middle East business.